<DOC>
	<DOCNO>NCT00191243</DOCNO>
	<brief_summary>Randomized , non-blinded , multi-center study patient metastatic breast cancer.Patients treat docetaxel docetaxel-gemcitabine . Aim study ass optimal dosage safety setting .</brief_summary>
	<brief_title>Docetaxel vs. Docetaxel-Gemcitabine Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>histologically verify diagnosis breast carcinoma , first diagnosis restrict previous adjuvant chemotherapy ( complete &gt; 6 month prior study ) measurable and/or nonmeasurable disease previous radiotherapy allow : terminate least 10 day prior sudy therapy , least one target lesion evaluation tumor response irradiate performance status 02 ( WHO , Zubrod ) adequate bone marrow reserve define adequate liver / renal function define prior systematic chemotherapy metastatic breast cancer expect survival time le 12 week past current history malignant neoplasm breast carcinoma except cured nonmelanoma skin cancer curatively treat situ carcinoma cervix uteri know brain metastases/leptomeningeal involvement active uncontrolled infection symptomatic peripheral neuropathy &gt; grade 2 accord NCI patient whose lesion assessable radionuclide scan patient sclerotic bone lesion site disease concomitant illness contraindication use corticosteroid concomitant serious illness medical condition , may worsen due treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>breast cancer</keyword>
</DOC>